Inhibition of alpha-1 adrenergic receptors by drugs such as tamsulosin and silodosin, which are prescribed for the treatment of benign prostatic hyperplasia, can lead to intraoperative floppy iris syndrome (IFIS) during cataract surgery. IFIS is a phenomenon characterized by a small, poorly dilating pupil and causes surgical difficulty.
Main objective: To determine and compare changes in the anatomical structure of the iris in patients with BPH before and after treatment with tamsulosin and silodosin.
Men aged 50 years and older with a definitive diagnosis of BPH who have no prior history of alpha-blocker use will be enrolled in one of the two treatment arms - tamsulosin or silodosin. Imaging will be performed using an MS-39 device (manufactured by CSO, Italy); assessments will be conducted at two time points - before the start of treatment and after three months of continuous drug use. At baseline and three months after treatment, using AS-OCT, the DMR and SMR regions and other ocular angle indices will be measured. Medication adherence will be assessed by counting the capsules used by each patient.
Specific Objectives:
1. To determine changes in the dilator muscle region (DMR) under scotopic, mesopic, photopic, and post-dilation conditions from baseline to the third month in the tamsulosin \& silodosin groups and compare them. 2. To determine changes in SMR under scotopic, mesopic, photopic, and post-dilation conditions from baseline to the third month in the tamsulosin \& silodosin groups and compare them.
Men ≥ 50 years old with a definitive diagnosis of BPH by a urologist colleague.
Patients with moderate symptoms based on the International Prostate Symptom Score (IPSS): score 8 to 19
No prior use of alpha-blockers (tamsulosin, silodosin, doxazosin, etc.)
Satisfactory vision for imaging and acceptable scan quality according to device criteria.
Insufficient image quality in assessments
History of intraocular surgery
Uncontrolled hypertension
Iris trauma
Parallel
tamsulosin 0.4mg
DrugTamsulosin 0.4 mg, daily.
Silodosin 8 mg
DrugSilodosin 8 mg, daily.
Changes in the dilator muscle region (DMR)
To determine changes in the DMR under scotopic, mesopic, photopic, and post-dilation conditions.
Changes in the sphincter muscle region (SMR)
To determine changes in the SMR under scotopic, mesopic, photopic, and post-dilation conditions.
Changes in the DMR/SMR ratio
To determine changes in the DMR/SMR ratio under scotopic, mesopic, photopic, and post-dilation conditions.
Click on the lead sponsor to view all of their trials.
Mohsen Pourazizi
Lead sponsor
Isfahan University of Medical Sciences
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
